Rifaximin-Mediated Changes to the Epithelial Cell Proteome: 2-D Gel Analysis

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Schrodt, Caroline ^a   McHugh, Erin E ^a   Gawinowicz, Mary Ann ^b   DuPont, Herbert L ^a,c   Brown, Eric L ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b Howard Hughes Medical Institute   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BINDING PROTEIN; FASCIN; HEAT SHOCK PROTEIN 90; HISTONE H4; LIPOCORTIN 5; PROTEOME; RETINOBLASTOMA BINDING PROTEIN 4; RIFAXIMIN; RNA;

ARTICLE; BACTERIAL COLONIZATION; CELL METABOLISM; CELL PROTECTION; CELL STRUCTURE; COLON FLORA; CYTOSKELETON; DOWN REGULATION; DRUG ABSORPTION; EPITHELIUM CELL; GENETIC TRANSCRIPTION; HOST CELL; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA TRANSLATION; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; VIRUS INFECTIVITY;

CELL LINE; DOWN-REGULATION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EPITHELIAL CELLS; HUMANS; PEPTIDES; PROTEOME; PROTEOMICS; RIFAMYCINS; UP-REGULATION;

EID: 84880834586     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068550     Document Type: Article

References (46)

1. DuPont HL, Haake R, Taylor DN, Ericsson CD, Jiang ZD, et al. (2007) Rifaximin treatment of pathogen-negative travelers' diarrhea. Journal of travel medicine 14: 16-19.
2. DuPont HL, Jiang ZD, (2004) Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 10: 1009-1011.
3. Infante RM, Ericsson CD, Jiang ZD, Ke S, Steffen R, et al. (2004) Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2: 135-138.
4. Leevy CB, Phillips JA, (2007) Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Digestive diseases and sciences 52: 737-741.
5. Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C, (2003) Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva gastroenterologica e dietologica 49: 53-62.
6. Steffen R, Sack DA, Riopel L, Jiang ZD, Sturchler M, et al. (2003) Therapy of travelers' diarrhea with rifaximin on various continents. The American journal of gastroenterology 98: 1073-1078.
7. Fumi AL, Trexler K, (2008) Rifaximin treatment for symptoms of irritable bowel syndrome. The Annals of pharmacotherapy 42: 408-412.
8. Gerard L, Garey KW, DuPont HL, (2005) Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert review of anti-infective therapy 3: 201-211.
9. Guslandi M, (2011) Rifaximin in the treatment of inflammatory bowel disease. World journal of gastroenterology: WJG 17: 4643-4646.
10. Isaacs KL, Sandler RS, Abreu M, Picco MF, Hanauer SB, et al. (2007) Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflammatory bowel diseases 13: 1250-1255.
11. Jolley J, (2011) High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. Clinical and experimental gastroenterology 4: 43-48.
12. DuPont HL, (2011) Biologic properties and clinical uses of rifaximin. Expert opinion on pharmacotherapy 12: 293-302.
13. Adachi JA, DuPont HL, (2006) Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 42: 541-547.
14. Brown EL, Xue Q, Jiang ZD, Xu Y, Dupont HL, (2010) Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrobial agents and chemotherapy 54: 388-396.
15. Logue SE, Elgendy M, Martin SJ, (2009) Expression, purification and use of recombinant annexin V for the detection of apoptotic cells. Nature protocols 4: 1383-1395.
16. Brest P, Betis F, Cuburu N, Selva E, Herrant M, et al. (2004) Increased rate of apoptosis and diminished phagocytic ability of human neutrophils infected with Afa/Dr diffusely adhering Escherichia coli strains. Infection and immunity 72: 5741-5749.
17. Samba-Louaka A, Nougayrede JP, Watrin C, Oswald E, Taieb F, (2009) The enteropathogenic Escherichia coli effector Cif induces delayed apoptosis in epithelial cells. Infection and immunity 77: 5471-5477.
18. Loukiadis E, Nobe R, Herold S, Tramuta C, Ogura Y, et al. (2008) Distribution, functional expression, and genetic organization of Cif, a phage-encoded type III-secreted effector from enteropathogenic and enterohemorrhagic Escherichia coli. Journal of bacteriology 190: 275-285.
19. Marches O, Ledger TN, Boury M, Ohara M, Tu X, et al. (2003) Enteropathogenic and enterohaemorrhagic Escherichia coli deliver a novel effector called Cif, which blocks cell cycle G2/M transition. Molecular microbiology 50: 1553-1567.
20. Figueiredo PM, Furumura MT, Aidar-Ugrinovich L, Pestana de Castro AF, Pereira FG, et al. (2007) Induction of apoptosis in Caco-2 and HT-29 human intestinal epithelial cells by enterohemolysin produced by classic enteropathogenic Escherichia coli. Letters in applied microbiology 45: 358-363.
21. Fernandez-Prada C, Tall BD, Elliott SE, Hoover DL, Nataro JP, et al. (1998) Hemolysin-positive enteroaggregative and cell-detaching Escherichia coli strains cause oncosis of human monocyte-derived macrophages and apoptosis of murine J774 cells. Infection and immunity 66: 3918-3924.
22. Chen KT, Malo MS, Moss AK, Zeller S, Johnson P, et al. (2010) Identification of specific targets for the gut mucosal defense factor intestinal alkaline phosphatase. American journal of physiology Gastrointestinal and liver physiology 299: G467-475.
23. Goldberg RF, Austen WG Jr, Zhang X, Munene G, Mostafa G, et al. (2008) Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. Proceedings of the National Academy of Sciences of the United States of America 105: 3551-3556.
24. Bates JM, Akerlund J, Mittge E, Guillemin K, (2007) Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. Cell host & microbe 2: 371-382.
25. Geddes K, Philpott DJ, (2008) A new role for intestinal alkaline phosphatase in gut barrier maintenance. Gastroenterology 135: 8-12.
26. Malo MS, Alam SN, Mostafa G, Zeller SJ, Johnson PV, et al. (2010) Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota. Gut 59: 1476-1484.
27. Tuin A, Poelstra K, de Jager-Krikken A, Bok L, Raaben W, et al. (2009) Role of alkaline phosphatase in colitis in man and rats. Gut 58: 379-387.
28. Lemaire S, Trinh TT, Le HT, Tang SC, Hincke M, et al. (2008) Antimicrobial effects of H4-(86-100), histogranin and related compounds-possible involvement of DNA gyrase. The FEBS journal 275: 5286-5297.
29. Richards RC, O'Neil DB, Thibault P, Ewart KV, (2001) Histone H1: an antimicrobial protein of Atlantic salmon (Salmo salar). Biochemical and biophysical research communications 284: 549-555.
30. Rose FR, Bailey K, Keyte JW, Chan WC, Greenwood D, et al. (1998) Potential role of epithelial cell-derived histone H1 proteins in innate antimicrobial defense in the human gastrointestinal tract. Infection and immunity 66: 3255-3263.
31. Fernandes JM, Kemp GD, Molle MG, Smith VJ, (2002) Anti-microbial properties of histone H2A from skin secretions of rainbow trout, Oncorhynchus mykiss. The Biochemical journal 368: 611-620.
32. Kim HS, Yoon H, Minn I, Park CB, Lee WT, et al. (2000) Pepsin-mediated processing of the cytoplasmic histone H2A to strong antimicrobial peptide buforin I. Journal of immunology. 165: 3268-3274.
33. Li GH, Mine Y, Hincke MT, Nys Y, (2007) Isolation and characterization of antimicrobial proteins and peptide from chicken liver. Journal of peptide science: an official publication of the European Peptide Society 13: 368-378.
34. Hirsch JG, (1958) Bactericidal action of histone. The Journal of experimental medicine 108: 925-944.
35. Li D, Roberts R, (2001) WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. Cellular and molecular life sciences: CMLS 58: 2085-2097.
36. Scuto A, Zhang H, Zhao H, Rivera M, Yeatman TJ, et al. (2007) RbAp48 regulates cytoskeletal organization and morphology by increasing K-Ras activity and signaling through mitogen-activated protein kinase. Cancer research 67: 10317-10324.
37. Nicolas E, Morales V, Magnaghi-Jaulin L, Harel-Bellan A, Richard-Foy H, et al. (2000) RbAp48 belongs to the histone deacetylase complex that associates with the retinoblastoma protein. The Journal of biological chemistry 275: 9797-9804.
38. Qualtrough D, Smallwood K, Littlejohns D, Pignatelli M, (2011) The actin-bundling protein fascin is overexpressed in inflammatory bowel disease and may be important in tissue repair. BMC gastroenterology 11: 14.
39. Takada M, Otaka M, Takahashi T, Izumi Y, Tamaki K, et al. (2010) Overexpression of a 60-kDa heat shock protein enhances cytoprotective function of small intestinal epithelial cells. Life sciences 86: 499-504.
40. Garrido C, Gurbuxani S, Ravagnan L, Kroemer G, (2001) Heat shock proteins: endogenous modulators of apoptotic cell death. Biochemical and biophysical research communications 286: 433-442.
41. Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, et al. (2000) Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nature cell biology 2: 469-475.
42. Pandey P, Saleh A, Nakazawa A, Kumar S, Srinivasula SM, et al. (2000) Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. The EMBO journal 19: 4310-4322.
43. Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES, (2000) Negative regulation of the Apaf-1 apoptosome by Hsp70. Nature cell biology 2: 476-483.
44. Lewis J, Devin A, Miller A, Lin Y, Rodriguez Y, et al. (2000) Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. The Journal of biological chemistry 275: 10519-10526.
45. Sato S, Fujita N, Tsuruo T, (2000) Modulation of Akt kinase activity by binding to Hsp90. Proceedings of the National Academy of Sciences of the United States of America 97: 10832-10837.
46. Zheng L, He M, Long M, Blomgran R, Stendahl O, (2004) Pathogen-induced apoptotic neutrophils express heat shock proteins and elicit activation of human macrophages. Journal of immunology 173: 6319-6326.